Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:PLRZ News 2 December 2025 - 4 December 2025

Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon Ltd. (NASDAQ: PLRZ) has gone from obscure micro‑cap to headline‑grabbing biotech in just two trading days. On December 4, 2025, the stock was changing hands in the mid‑teens, more than doubling from the prior close of $7.09, with intraday swings between roughly $12.5 and $18.2 and volume near 26 million shares – over 20× its recent average. MarketBeat+1 Behind this violent move are two concrete catalysts: At the same time, quantitative services and technical models are sending mixed—and often cautious—signals, with several “Strong Sell” ratings even as momentum screens flash “Buy” or “Strong Buy.” TipRanks+4Danelfin AI+4TradingView+4 This article walks
4 December 2025
···
Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025

Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025

Polyrizon Ltd. (NASDAQ: PLRZ) has exploded into the spotlight after a two‑day run that has turned an obscure micro‑cap biotech into one of the most talked‑about healthcare stocks on the Nasdaq. By early afternoon on December 4, 2025, Polyrizon shares were trading around $13–15, nearly doubling from Wednesday’s close at $7.09, with intraday highs reported above $18 and gains briefly exceeding 100–130%, according to MarketBeat, Investing.com and other real‑time data providers. 24/7 MarketNews+3MarketBeat+3StockAnalysis+3 At the heart of this move are two catalysts: Together, these updates have ignited speculative interest in a company that, until recently, was fighting to stay listed
4 December 2025
··
Polyrizon Ltd (PLRZ) Stock Soars on Nasal Spray Milestone: Latest News, AI Forecasts and Risk Outlook – December 3, 2025

Polyrizon Ltd (PLRZ) Stock Soars on Nasal Spray Milestone: Latest News, AI Forecasts and Risk Outlook – December 3, 2025

Polyrizon Ltd (NASDAQ: PLRZ) has suddenly jumped from obscure micro‑cap to headline mover. On Tuesday, December 2, 2025, the Israeli biotech’s shares spiked roughly 130% in a single session after the company announced a key manufacturing upscaling milestone for its PL‑14 nasal allergy blocker platform. The stock closed at about $7.33 on Tuesday—up from $3.16 the prior session—with intraday highs above $8 and trading volume near 150 million shares. Pre‑market quotes on December 3 show the stock around $6, still dramatically higher than earlier in the week. StockAnalysis+1 The move comes from a tiny base. Polyrizon is a development‑stage biotech
3 December 2025
··
Polyrizon (PLRZ) Stock Soars Over 130% on Nasal Spray Breakthrough: Is This Micro-Cap Biotech the Next Big Winner or a Speculative Trap?

Polyrizon (PLRZ) Stock Soars Over 130% on Nasal Spray Breakthrough: Is This Micro-Cap Biotech the Next Big Winner or a Speculative Trap?

On December 2, 2025, Polyrizon Ltd. (NASDAQ: PLRZ) went from obscure micro-cap to center stage as its stock exploded more than 130% in a single session after the company announced a key manufacturing milestone for its flagship nasal spray platform.MarketScreener+1 The move capped one of the wildest trading days the stock has seen since its 2024 IPO: shares closed around $7.33, up 131.96% on the day, with intraday prices swinging between $5.85 and $8.36 and volume surging past 148 million shares.StockAnalysis Other outlets tracking real‑time tape during the session quoted gains ranging from roughly 80% to 142%, depending on the
2 December 2025
·

Stock Market Today

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company projected about $200 billion in 2026 capital expenditures, triggering investor concern over AI spending. The stock had already dropped 11.5% after-hours Thursday. Amazon forecast Q1 net sales of $173.5–$178.5 billion and operating income of $16.5–$21.5 billion. Analyst Gil Luria downgraded Amazon, citing rising investment as its cloud lead narrows.
AMD stock jumps 8% in chip rebound — what investors are watching before Monday

AMD stock jumps 8% in chip rebound — what investors are watching before Monday

7 February 2026
AMD shares jumped 8.2% to $208.44 Friday, trading on heavy volume as chip stocks rebounded and the Dow closed above 50,000 for the first time. The Philadelphia Semiconductor Index rose 5.7% after Amazon’s AI spending plans lifted sector estimates. Nvidia’s CEO cited surging AI chip demand. AMD’s rally followed a weak revenue outlook earlier in the week.
Alphabet stock drops for a fourth straight day as AI spending jitters linger

Alphabet stock drops for a fourth straight day as AI spending jitters linger

7 February 2026
Alphabet shares fell 2.53% to $322.86 Friday, marking a fourth straight decline as investors questioned heavy AI-related spending. The Nasdaq slipped Thursday after Alphabet detailed up to $185 billion in capex, while the Dow and S&P 500 rose Friday on chipmaker gains. U.S. markets reopen Monday, with attention on Alphabet’s outlook and upcoming jobs and inflation data.
Go toTop